Clinical observations related to head lice infestation

https://doi.org/10.1016/0190-9622(91)70190-DGet rights and content

Living lice and eggs were found in 19% of 2643 children examined in Israel. Boys and girls were equally infested. Bite reactions, pruritus, excoriations, lymphadenopathy, and conjunctivitis were the most common signs and symptoms. Bite reactions, pruritus, excoriations, and conjunctivitis were found more frequently in infested children than in noninfested children. Lymphadenopathy, eczema, influenza, herpes, crusts behind ears, blepharitis, seborrhea, psoriasis, erythema, vitiligo, secondary infections, and scars were equally common in both groups. The sequence of the skin reactions of a volunteer to continuous exposure to lice bites was as follow: phase I, no clinical symptoms; phase II, papules accompanied by pruritus of medium intensity; phase III, wheal formation immediately after the bite, followed by a delayed papular reaction and intense itching; phase IV, papular reaction with diminished reactivity of the skin and mild pruritus. Healed bite reactions reappeared when other parts of the skin were again exposed to the lice.

References (16)

  • D Tamir et al.

    Prevalence of head lice in school in Jerusalem during 1979-1982

    Harefuah

    (1984)
  • B Sarov et al.

    Evaluation of an intervention program for head lice infestation in school children

    Pediatr Infest Dis J

    (1988)
  • KY Mumcuoglu

    Head lice in Israel

    Fam Physician

    (1988)
  • KY Mumcuoglu et al.

    Epidemiological studies on head lice infestation in Israel. I. Parasitological examination of children

    Int J Dermatol

    (1990)
  • F Rochese

    Generalized dermatitis from Pediculosis capitis

    N Engl J Med

    (1946)
  • CA Frazier
  • E Epstein et al.

    Pediculosis: clinical aspects

  • JA Withowski et al.

    The usual and not so usual forms of pediculosis

There are more references available in the full text version of this article.

Cited by (0)

Supported by a grant (ISR/VBC/001) of the World Health Organization—Europe, the Nicholas Fund, and Teva and Abic Pharmaceuticals Ltd., Jerusalem

View full text